Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hepatitis c pill aims to cut treatment time in half

NCT ID NCT06868264

Disease control Sponsor: Atea Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial compares a new two-drug combination pill (Bemnifosbuvir-Ruzasvir) against the current standard treatment (Sofosbuvir-Velpatasvir) for adults with chronic hepatitis C. About 880 participants who have not been treated with similar drugs before will take the new pill for 8 or 12 weeks, depending on liver health. The goal is to see if the new treatment works just as well or better at clearing the virus.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Bemnifosbuvir-Ruzasvir (BEM/RZR) fixed-dose combination
What this could lead to
If successful, this could provide a shorter, 8-week treatment option for many people with chronic hepatitis C, potentially improving convenience and adherence.
What could go wrong
This is a Phase 3 trial, but results are not yet available. The new drug may not be as effective or safe as the current standard treatment, and side effects are possible.
Why investors are watching

ATEA Pharmaceuticals is running a Phase 3 trial comparing its experimental hepatitis C pill, Bemnifosbuvir-Ruzasvir, against an established standard treatment in 880 adults. For a small company, this readout is the main test of whether its drug can match or beat an existing option, which would determine its commercial future.

If it works: If the trial shows the drug works as well or better with fewer side effects, ATEA could gain a foothold in the hepatitis C market and generate revenue from a drug it owns outright.

If it fails: The trial could fail to show the drug is as good as the standard, or the company could face delays. Hepatitis C already has effective cures, so a failure would likely leave ATEA without a viable product and hurt its stock.

AI-written from the trial record. Speculative, and not investment advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 880 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Use of adequate contraception for females of childbearing potential * Must be direct-acting antiviral (DAA)-treatment-naïve (never exposed to an approved or experimental DAA for HCV) * Documented medical history compatible with chronic HCV * Either no liver cirrhosis or with compensated liver cirrhosis * If HIV-1-positive, must meet the following 2 criteria: 1. Antiretroviral (ARV) regimen for \>8 weeks prior to screening visit, with CD4 T-cell count \>200 cells/mm3 and plasma HIV-1 RNA \<LLOQ 2. Suitable ARV treatment and not taking any contraindicated medications Key Exclusion Criteria: * Pregnant or breastfeeding * Co-infected with hepatitis B virus * Abuse of alcohol and/or illicit drug use that could interfere with adherence to study requirements as judged by the investigator * Requirement of any prohibited medications * Use of other investigational drugs within 30 days of dosing * History or signs of decompensated liver disease (decompensated cirrhosis) * History of hepatocellular carcinoma (HCC) * Any other clinically significant medical condition that, in the opinion of the investigator, would jeopardize the safety of the subject or impact the validity of the study results

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatitis C virus chronic infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic hepatitis C virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatitis C virus chronic infection

Contacts and locations

Locations

  • Atea Study Site

    Birmingham, Alabama, 35215, United States

  • Atea Study Site

    Dothan, Alabama, 36301, United States

  • Atea Study Site

    Chandler, Arizona, 85225, United States

  • Atea Study Site

    Flagstaff, Arizona, 86001, United States

  • Atea Study Site

    Mesa, Arizona, 85210, United States

  • Atea Study Site

    Phoenix, Arizona, 85006, United States

  • Atea Study Site

    Phoenix, Arizona, 85015, United States

  • Atea Study Site

    Tucson, Arizona, 85745, United States

  • Atea Study Site

    Little Rock, Arkansas, 72204, United States

  • Atea Study Site

    Bakersfield, California, 93301, United States

  • Atea Study Site

    Coronado, California, 92118, United States

  • Atea Study Site

    Escondido, California, 92025, United States

  • Atea Study Site

    Fresno, California, 93711, United States

  • Atea Study Site

    Long Beach, California, 98015, United States

  • Atea Study Site

    Los Angeles, California, 90048, United States

  • Atea Study Site

    Los Angeles, California, 90067, United States

  • Atea Study Site

    Orange, California, 92868, United States

  • Atea Study Site

    Pasadena, California, 91105, United States

  • Atea Study Site

    Sacramento, California, 95817, United States

  • Atea Study Site

    Torrance, California, 90502, United States

  • Atea Study Site

    Valencia, California, 91355, United States

  • Atea Study Site

    Colorado Springs, Colorado, 80907, United States

  • Atea Study Site

    Washington D.C., District of Columbia, 20017, United States

  • Atea Study Site

    Washington D.C., District of Columbia, 20037, United States

  • Atea Study Site

    Coral Gables, Florida, 33134, United States

  • Atea Study Site

    DeLand, Florida, 32720, United States

  • Atea Study Site

    Fort Lauderdale, Florida, 33308, United States

  • Atea Study Site

    Ft. Pierce, Florida, 34982, United States

  • Atea Study Site

    Gainesville, Florida, 32610, United States

  • Atea Study Site

    Inverness, Florida, 34452, United States

  • Atea Study Site

    Jupiter, Florida, 33458, United States

  • Atea Study Site

    Lauderdale Lakes, Florida, 33313, United States

  • Atea Study Site

    Maitland, Florida, 32751, United States

  • Atea Study Site

    Miami, Florida, 33125, United States

  • Atea Study Site

    Miami Lakes, Florida, 33014, United States

  • Atea Study Site

    Orlando, Florida, 32803, United States

  • Atea Study Site

    Pembroke Pines, Florida, 33024, United States

  • Atea Study Site

    Sarasota, Florida, 34237, United States

  • Atea Study Site

    West Palm Beach, Florida, 33407, United States

  • Atea Study Site

    Macon, Georgia, 31201, United States

  • Atea Study Site

    Marietta, Georgia, 30060, United States

  • Atea Study Site

    Chicago, Illinois, 60613, United States

  • Atea Study Site

    New Albany, Indiana, 47150, United States

  • Atea Study Site

    Fairway, Kansas, 66205, United States

  • Atea Study Site

    Topeka, Kansas, 66606, United States

  • Atea Study Site

    Louisville, Kentucky, 40218, United States

  • Atea Study Site

    New Iberia, Louisiana, 70560, United States

  • Atea Study Site

    New Orleans, Louisiana, 70112, United States

  • Atea Study Site

    Baltimore, Maryland, 21201, United States

  • Atea Study Site

    Baltimore, Maryland, 21287, United States

  • Atea Study Site

    Boston, Massachusetts, 02114, United States

  • Atea Study Site

    Boston, Massachusetts, 02118, United States

  • Atea Study Site

    Springfield, Massachusetts, 01105, United States

  • Atea Study Site

    Worcester, Massachusetts, 01655, United States

  • Atea Study Site

    Detroit, Michigan, 48201, United States

  • Atea Study Site

    Grosse Pointe Woods, Michigan, 48236, United States

  • Atea Study Site

    Novi, Michigan, 48377, United States

  • Atea Study Site

    Wyoming, Michigan, 49519, United States

  • Atea Study Site

    Tupelo, Mississippi, 38801, United States

  • Atea Study Site

    Camden, New Jersey, 08103, United States

  • Atea Study Site

    Hackensack, New Jersey, 07601, United States

  • Atea Study Site

    Hillsborough, New Jersey, 08844, United States

  • Atea Study Site

    Newark, New Jersey, 07102, United States

  • Atea Study Site

    Newark, New Jersey, 07103, United States

  • Atea Study Site

    Brooklyn, New York, 11215, United States

  • Atea Study Site

    New York, New York, 10016, United States

  • Atea Study Site

    Yonkers, New York, 10701, United States

  • Atea Study Site

    Asheville, North Carolina, 28801, United States

  • Atea Study Site

    Charlotte, North Carolina, 28204, United States

  • Atea Study Site

    Fayetteville, North Carolina, 28304, United States

  • Atea Study Site

    Beavercreek, Ohio, 45440, United States

  • Atea Study Site

    Cincinnati, Ohio, 45267, United States

  • Atea Study Site

    Tulsa, Oklahoma, 74104, United States

  • Atea Study Site

    Allentown, Pennsylvania, 18103, United States

  • Atea Study Site

    DuBois, Pennsylvania, 15801, United States

  • Atea Study Site

    Philadelphia, Pennsylvania, 19104, United States

  • Atea Study Site

    Philadelphia, Pennsylvania, 19107, United States

  • Atea Study Site

    Charleston, South Carolina, 29425, United States

  • Atea Study Site

    Chattanooga, Tennessee, 37421, United States

  • Atea Study Site

    Cordova, Tennessee, 38018, United States

  • Atea Study Site

    Jackson, Tennessee, 38301, United States

  • Atea Study Site

    Arlington, Texas, 76012, United States

  • Atea Study Site

    Dallas, Texas, 75203, United States

  • Atea Study Site

    Dallas, Texas, 75242, United States

  • Atea Study Site

    Denison, Texas, 75020, United States

  • Atea Study Site

    Houston, Texas, 77030, United States

  • Atea Study Site

    Plano, Texas, 75093, United States

  • Atea Study Site

    San Antonio, Texas, 78215, United States

  • Atea Study Site

    Temple, Texas, 76508, United States

  • Atea Study Site

    Waco, Texas, 76710, United States

  • Atea Study Site

    Ogden, Utah, 84405, United States

  • Atea Study Site

    Chesapeake, Virginia, 23320, United States

  • Atea Study Site

    Norfolk, Virginia, 23502, United States

  • Atea Study Site

    Richmond, Virginia, 23226, United States

  • Atea Study Site

    Richmond, Virginia, 23298, United States

  • Atea Study Site

    Seattle, Washington, 98101, United States

  • Atea Study Site

    Vancouver, British Columbia, V6Z 2C7, Canada

  • Atea Study Site

    Moncton, New Brunswick, E1C6Z8, Canada

  • Atea Study Site

    St. John's, Newfoundland and Labrador, A1B3V6, Canada

  • Atea Study Site

    Brampton, Ontario, L6R 3J7, Canada

  • Atea Study Site

    Ottawa, Ontario, K1H8L6, Canada

  • Atea Study Site

    Toronto, Ontario, M5G2C4, Canada

  • Atea Study Site

    Montreal, Quebec, H4A3J1, Canada

  • Atea Study Site

    Québec, Quebec, G1V 4T3, Canada

  • Atea Study Site

    Québec, Quebec, G1V4G2, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.